Digital perioperative rehabilitation for gastric cancer surgery after neoadjuvant therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized interventional trial compares three approaches: multimodal perioperative rehabilitation with digital supervision, the same program with telephone supervision, and usual care for patients undergoing neoadjuvant therapy and surgery for resectable gastric cancer. The rehabilitation program combines exercise, nutritional support, and psychological guidance delivered before and after surgery. Primary endpoints include postoperative complication rates and perioperative clinical indices such as functional capacity (6MWT), nutritional status, and psychological measures, and a key secondary endpoint is patient adherence as tracked by the smartphone platform. Participants are adults aged 18–70 treated at Beijing Friendship Hospital and will attend planned in-person and digital follow-ups.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients aged between 18 and 70 years;
* patients with histologically confirmed resectable adenocarcinoma of the oesophago gastric junction or stomach;
* patients referred by a multidisciplinary team (MDT) for neoadjuvant therapy;
* patients able to use a smartphone and the digital follow up platform, and willing to comply with regular follow up assessments;
* patients who provide written informed consent.

Exclusion Criteria:

* presence of distant metastasis;
* severe cardiopulmonary disease or other contraindications precluding completion of the 6MWT or participation in exercise training;
* concurrent other malignant tumours;
* suspected recurrent gastric cancer;
* cognitive impairment, communication barriers, or psychiatric conditions that would prevent compliance with the study procedures;
* women who are pregnant, lactating, or planning a pregnancy.

Where it's running

• Beijing Friendship Hospital, Capital Medical University
  Beijing, China Recruiting

Study contacts

• Study coordinator: Zhi Zheng, Attending surgon
• Email: zhengzhi@ccmu.edu.cn
• Phone: +86-13811132175

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment

  This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07816263

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.